News

News


12 Apr 2010
IJTLD The International Journal of Tuberculosis and Lung Disease (IJTLD) is the official publication of the International Union Against Tuberculosis and Lung Disease (The Union). The IJTLD is the reference for clinical research and epidemiological studies on tuberculosis. It is also the only peer-...
7 Apr 2010
In Memoriam: Karel De Beule Post provided by Dr. Beule’s colleagues at Tibotec. In memoriam: Karel De Beule, PharmD, MBA (July 8, 1958 – April 6, 2010) following an outstanding 24+ year career in the pharmaceutical industry; Karel will be remembered for his contributions to pharmaceutical...
7 Apr 2010
Dr. Denis Mitchison in the lab When you think of true pioneers in research and development for the treatment of infectious diseases, Dr. Dennis Mitchison is sure to come to mind. Born on September 6, 1916, Dr. Mitchison has had a long career dedicated to treating tuberculosis. After qualifying in...
5 Apr 2010
Many antibiotics used today to fight and control M. tb infection target cell wall synthesis or DNA replication, and related pathogen growth mechanisms. A recent report by Zhou et al. in PNAS at the beginning of year, suggested an alternate mechanism for M. tb elimination; targeting MptpB, a...
31 Mar 2010
Dr. Stewart Cole Stewart Cole helped create the Global Health Institute in 2007. Located at the Ecole polytechnique fédérale de Lausanne (EPFL), will use cutting-edge techniques to seek solutions to tuberculosis, a growing threat worldwide. Dr Cole’s work on tuberculosis, leprosy, AIDS, gas...
30 Mar 2010
This article originally appeared in The Guardian The fund that fights killer diseases such as TB and Aids needs to build on its success, but it is facing a fiscal crisis by Jeffrey Sachs More than 100m long-lasting insecticide-treated bed nets have been distributed in the fight against malaria...
29 Mar 2010
Rat TB testing apparatus The use of animal models for drug discovery is a key step in the process. Rodents, in particular mice, have been indispensible for understanding the pharmacodynamics (what the drug does to the body) and pharmacokinetics (the time-course of how the body handles the drug) of...
24 Mar 2010
FT Combating Tuberculosis Special Report The Financial Times created a special report on “Combating Tuberculosis” that was published for World TB Day on March 24, 2010. Articles in the special report include: Complacency is one of the greatest risks Treatment is too complex and too slow Mobile X-...
24 Mar 2010
FT.com For World TB Day, the Financial Times’ Andrew Jack interviewed various members of the TB community to get their take on a range of topics: Paul Stoffels, head of R&D at Johnson & Johnson , explains why drugs to cope with tuberculosis have been slow to emerge from the pipelines of the...
24 Mar 2010
CPTR could deliver a new TB regimen in just 6 years as opposed to 24 After a decades-long drought, new pharmaceutical discoveries and repurposing of existing antimicrobials have produced about 10 drugs from 7 different classes which are now in various stages of clinical development for TB. Many...
22 Mar 2010
www.aeras.org 8 million GBP will support the fight against tuberculosis Rockville, Maryland, USA, March 23, 2010 – Global efforts to combat tuberculosis gained momentum today when the government of the United Kingdom announced generous funding to the Aeras Global TB Vaccine Foundation . The first-...
22 Mar 2010
NYAS In more than 10 years since the sequence of the Mycobacterium tuberculosis genome was published, the genetic information of the pathogen and genetic tools have shifted the emphasis of TB drug research. This symposium highlights how they are utilized in the quest for novel TB regimens. This...
22 Mar 2010
worldTBday.org This Wednesday, March 24 th , is World TB Day. With 1.7 million people dying every year and one-third of the world infected, the time to act is now! Follow the day’s events at http://www.WorldTBDay.org . State-by-state activities can also be found at the CDC’s website by clicking...
18 Mar 2010
World Health Organization 18 MARCH 2010 | GENEVA | WASHINGTON DC — In some areas of the world, one in four people with tuberculosis (TB) becomes ill with a form of the disease that can no longer be treated with standard drugs regimens, a World Health Organization (WHO) report says. For example, 28...
17 Mar 2010
Today marks the launch of an exciting new initiative in TB R&D. The US Food and Drug Administration (FDA) has supported the Critical Path to TB Drug Regimens (CPTR). The CPTR comprises a broad collaborative network of partners including pharmaceutical companies, government, academia, and...

Pages